CCCC

CCCC

USD

C4 Therapeutics Inc. Common Stock

$2.325-0.025 (-1.064%)

Preço em tempo real

Healthcare
Biotecnologia
Estados Unidos

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado
Fundamentos da empresa
Estatísticas de negociação

Métricas de mercado

Abertura

$2.350

Máximo

$2.420

Mínimo

$2.290

Volume

1.58M

Fundamentos da empresa

Capitalização de mercado

225.3M

Setor

Biotecnologia

País

United States

Estatísticas de negociação

Volume médio

1.92M

Bolsa de valores

NMS

Moeda

USD

Faixa de 52 semanas

Mínimo $1.085Atual $2.325Máximo $6.2

Notícias relacionadas

Analyst Upgrades

Wells Fargo Maintains Overweight on C4 Therapeutics, Raises Price Target to $10

Wells Fargo analyst Derek Archila maintains C4 Therapeutics with a Overweight and raises the price target from $5 to $10.

Ver mais
Wells Fargo Maintains Overweight on C4 Therapeutics, Raises Price Target to $10
Analyst Upgrades

Stephens & Co. Reiterates Overweight on C4 Therapeutics, Maintains $6 Price Target

Stephens & Co. analyst Sudan Loganathan reiterates C4 Therapeutics with a Overweight and maintains $6 price target.

Ver mais
Stephens & Co. Reiterates Overweight on C4 Therapeutics, Maintains $6 Price Target
GlobeNewswire

C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting

Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple

Ver mais
C4 Therapeutics Presents Cemsidomide Phase 1 Multiple Myeloma Data Supporting Potential Best-in-Class Profile at the International Myeloma Society Annual Meeting
Analyst Upgrades

Barclays Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $8

Barclays analyst Etzer Darout initiates coverage on C4 Therapeutics with a Overweight rating and announces Price Target of $8.

Ver mais
Barclays Initiates Coverage On C4 Therapeutics with Overweight Rating, Announces Price Target of $8
Analyst Upgrades

Stephens & Co. Upgrades C4 Therapeutics to Overweight, Raises Price Target to $6

Stephens & Co. analyst Sudan Loganathan upgrades C4 Therapeutics from Equal-Weight to Overweight and raises the price target from $3 to $6.

Ver mais
Stephens & Co. Upgrades C4 Therapeutics to Overweight, Raises Price Target to $6
PR Newswire

Breakthrough Therapy Designations Surge as $50B Cancer Drug Partnerships Reshape Market

USA News Group News Commentary – The FDA's unprecedented wave of Breakthrough Therapy Designations through August has accelerated development...

GlobeNewswire

C4 Therapeutics Highlights Recent Achievement in Biogen Collaboration

WATERTOWN, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- C4 Therapeutics, Inc. (C4T) (NASDAQ:CCCC), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced

Mantenha-se atualizado

Defina um alerta de preço, obtenha atualizações de análise de IA e notícias de mercado em tempo real.